Name: BMS-986365 Cat#: EX-A8829

Target:: Androgen Receptor
Pathway: Vitamin D Related/Nuclear Receptor

Chemical Structure:



Chemical Name	1-Piperazineacetamide, 4-[2-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-ethylphenoxy]ethyl]-N-[3-[(2,6-dioxo-3-piperidinyl)amino]phenyl]-2-methyl-, (2R)-

Molecular Weight	818.907	Storage	3 years -20°C powder 6 months -80°C in solvent Away from light
Formula	C41H45F3N8O5S		
CAS No.	2446928-30-7	Synonyms	CC-94676

Solubility (25°C) *	In vitro	DMSO	Soluble
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.2211 mL	6.1057 mL	12.2114 mL
5 mM	0. 2442 mL	1.2211 mL	2.4423 mL
10 mM	0. 1221 mL	0. 6106 mL	1.2211 mL

*The above data is based on the product molecular weight 818.91.

Biological Activities:

Description	BMS-986365 is a selective heterobifunctional ligand-directed degrader (LDD) targeting the androgen receptor (AR). BMS-986365 demonstrated significant in vivo potency, degrading AR, inhibiting AR signaling, and inhibiting tumor growth in animal models of advanced prostate cancer.

References	[1]. [1]. Xu S, et al. Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer[J]. Cancer Research, 2024, 84(7_Supplement): ND02-ND02.